BR112014029149A2 - biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular - Google Patents
biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascularInfo
- Publication number
- BR112014029149A2 BR112014029149A2 BR112014029149A BR112014029149A BR112014029149A2 BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2 BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A BR112014029149 A BR 112014029149A BR 112014029149 A2 BR112014029149 A2 BR 112014029149A2
- Authority
- BR
- Brazil
- Prior art keywords
- implants
- drug
- magnetic resonance
- vascular occlusion
- eluting
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title abstract 4
- 206010053648 Vascular occlusion Diseases 0.000 title abstract 3
- 239000007943 implant Substances 0.000 title abstract 3
- 208000021331 vascular occlusion disease Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651389P | 2012-05-24 | 2012-05-24 | |
| PCT/US2013/042363 WO2013177364A1 (en) | 2012-05-24 | 2013-05-23 | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014029149A2 true BR112014029149A2 (pt) | 2017-06-27 |
Family
ID=49621771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014029149A BR112014029149A2 (pt) | 2012-05-24 | 2013-05-23 | biomateriais adequados para uso como implantes eluíveis por fármacos e detectáveis por ressonância magnética para oclusão vascular |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10695440B2 (enExample) |
| EP (2) | EP3295961B1 (enExample) |
| JP (1) | JP6208749B2 (enExample) |
| BR (1) | BR112014029149A2 (enExample) |
| CA (1) | CA2866896C (enExample) |
| ES (1) | ES2655656T3 (enExample) |
| WO (1) | WO2013177364A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3295961B1 (en) | 2012-05-24 | 2020-04-08 | Biosphere Medical Inc. | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
| CN110279885B (zh) | 2013-09-19 | 2022-07-26 | 泰尔茂株式会社 | 聚合物颗粒 |
| BR112016005768B1 (pt) | 2013-09-19 | 2021-09-21 | Microvention, Inc | Películas de polímero |
| BR112016010067B1 (pt) | 2013-11-08 | 2023-01-10 | Terumo Corporation | Partículas de polímero e métodos de preparação |
| US9907880B2 (en) | 2015-03-26 | 2018-03-06 | Microvention, Inc. | Particles |
| KR102310696B1 (ko) | 2016-09-28 | 2021-10-12 | 테루모 가부시키가이샤 | 색전 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509858A (enExample) | 1973-06-02 | 1975-01-31 | ||
| JPS6056676B2 (ja) | 1980-07-18 | 1985-12-11 | 日立造船株式会社 | コンクリ−ト複合パネル |
| ATE130517T1 (de) | 1990-08-08 | 1995-12-15 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. |
| FR2676927B1 (fr) * | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
| US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
| US6315709B1 (en) * | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
| WO2001072281A2 (en) | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for active embolization |
| FR2808026B1 (fr) | 2000-04-25 | 2002-06-14 | Alexandre Laurent | Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau |
| JP2005053707A (ja) | 2001-07-30 | 2005-03-03 | Kankyo Device Kenkyusho:Kk | 可視光応答性材料の製造方法 |
| US7462366B2 (en) * | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US8012454B2 (en) * | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| JP4909071B2 (ja) * | 2003-03-24 | 2012-04-04 | プルーローメッド， インコーポレイテッド | 逆感熱性ポリマーを使用する一時的な塞栓形成 |
| WO2005044224A2 (en) | 2003-05-02 | 2005-05-19 | Case Western Reserve University | Drug delivery system based on polymer nanoshells |
| AU2005277542B2 (en) * | 2004-08-19 | 2011-11-17 | Covidien Lp | Water-swellable copolymers and articles and coating made therefrom |
| WO2009073193A2 (en) | 2007-12-03 | 2009-06-11 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| GB0807154D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Aston | Intervertebral disc |
| US9115238B2 (en) * | 2009-05-28 | 2015-08-25 | Corning Incorporated | Swellable synthetic microcarriers for culturing cells |
| EP2451488A2 (en) * | 2009-07-07 | 2012-05-16 | Bartling, Sönke | Multimodal visible polymer embolization material |
| EP3295961B1 (en) | 2012-05-24 | 2020-04-08 | Biosphere Medical Inc. | Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion |
-
2013
- 2013-05-23 EP EP17193907.7A patent/EP3295961B1/en active Active
- 2013-05-23 CA CA2866896A patent/CA2866896C/en active Active
- 2013-05-23 ES ES13794343.7T patent/ES2655656T3/es active Active
- 2013-05-23 BR BR112014029149A patent/BR112014029149A2/pt not_active Application Discontinuation
- 2013-05-23 US US13/900,796 patent/US10695440B2/en active Active
- 2013-05-23 WO PCT/US2013/042363 patent/WO2013177364A1/en not_active Ceased
- 2013-05-23 JP JP2015514174A patent/JP6208749B2/ja active Active
- 2013-05-23 EP EP13794343.7A patent/EP2854869B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2854869A4 (en) | 2015-12-30 |
| CA2866896A1 (en) | 2013-11-28 |
| US20130315838A1 (en) | 2013-11-28 |
| JP2015517390A (ja) | 2015-06-22 |
| EP2854869B1 (en) | 2017-11-01 |
| EP2854869A1 (en) | 2015-04-08 |
| WO2013177364A1 (en) | 2013-11-28 |
| ES2655656T3 (es) | 2018-02-21 |
| EP3295961A1 (en) | 2018-03-21 |
| JP6208749B2 (ja) | 2017-10-04 |
| EP3295961B1 (en) | 2020-04-08 |
| US10695440B2 (en) | 2020-06-30 |
| CA2866896C (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| BR112013018534A2 (pt) | marcadores de mri, sistemas de entrega e extração e métodos de fabricação e uso dos mesmos | |
| CY1118105T1 (el) | Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα | |
| BR112013027500A2 (pt) | liberação controlada de imunossupressores de nanotransportadores sintéticos | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX365521B (es) | Polimeros que contienen zwiteriones de alto peso molecular. | |
| GB201113856D0 (en) | Medical device | |
| IN2014DN11201A (enExample) | ||
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20150217A (es) | Inhibidores de histona demetilasas | |
| IN2014DN10161A (enExample) | ||
| CL2012003385A1 (es) | Tratamiento para la incontinencia. | |
| MX344528B (es) | Sistemas y metodos para determinar la idoneidad de un implante mecanico para un procedimiento medico. | |
| BR112017001049A2 (pt) | material biocomposto anisotrópico, implantes médicos contendo o mesmo e métodos de tratamento do mesmo | |
| SG11201506260WA (en) | Biodegradable metallic medical implants, method for preparing and use thereof | |
| UY34539A (es) | Heteroarilos y usos de los mismos | |
| MX2015015409A (es) | Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos. | |
| SG11201508680VA (en) | New carbodiimides having terminal urea and/or urethane groups, methods for producing said carbodiimides, and use of said carbodiimides | |
| PH12014500686A1 (en) | Implantable medical devices with increased immune tolerance, and methods for making and implanting | |
| MX365403B (es) | Peptidos y metodos para usarlos. | |
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| EP3579888C0 (en) | ELECTROCHEMICAL GAS TRANSMITTER GENERATING COMPOSITIONS AND METHODS OF USE THEREOF AND DRESSINGS AND TREATMENT SYSTEMS INCORPORATING THE SAME | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular | |
| IN2014DN10765A (enExample) | ||
| MX345351B (es) | Compuesto macrociclico y metodos para su produccion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |